Scinai Immunotherapeutics Files Updated Business Presentation
Ticker: SCNI · Form: 6-K · Filed: Apr 16, 2024 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Apr 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing-update, presentation
TL;DR
Scinai dropped a new investor deck, check it for updates.
AI Summary
Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) has filed a Form 6-K on April 16, 2024, to provide an updated business presentation. This filing incorporates an updated presentation as Exhibit 99.1, which contains new business updates.
Why It Matters
Investors and stakeholders can review the latest business developments and strategic updates from Scinai Immunotherapeutics through this newly filed presentation.
Risk Assessment
Risk Level: low — This filing is an informational update and does not contain significant financial or operational changes that would immediately impact risk.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Filer
- BiondVax Pharmaceuticals Ltd. (company) — Former company name
- April 16, 2024 (date) — Filing date
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report that Scinai Immunotherapeutics Ltd. has made available an updated presentation about its business, incorporated as Exhibit 99.1.
What is the filing date of this report?
The filing date of this report is April 16, 2024.
What was Scinai Immunotherapeutics Ltd. formerly known as?
Scinai Immunotherapeutics Ltd. was formerly known as BiondVax Pharmaceuticals Ltd.
Where is Scinai Immunotherapeutics Ltd. located?
Scinai Immunotherapeutics Ltd. is located at Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel.
Does the registrant file annual reports under Form 20-F or Form 40-F?
The registrant, Scinai Immunotherapeutics Ltd., indicates that it files annual reports under Form 20-F.
Filing Stats: 245 words · 1 min read · ~1 pages · Grade level 12.9 · Accepted 2024-04-16 17:27:06
Filing Documents
- ea0203981-6k_scinai.htm (6-K) — 11KB
- ea020398101ex99-1_scinai.htm (EX-99.1) — 53KB
- ex99-1_001.jpg (GRAPHIC) — 221KB
- ex99-1_002.jpg (GRAPHIC) — 322KB
- ex99-1_003.jpg (GRAPHIC) — 323KB
- ex99-1_004.jpg (GRAPHIC) — 324KB
- ex99-1_005.jpg (GRAPHIC) — 423KB
- ex99-1_006.jpg (GRAPHIC) — 310KB
- ex99-1_007.jpg (GRAPHIC) — 372KB
- ex99-1_008.jpg (GRAPHIC) — 243KB
- ex99-1_009.jpg (GRAPHIC) — 312KB
- ex99-1_010.jpg (GRAPHIC) — 205KB
- ex99-1_011.jpg (GRAPHIC) — 235KB
- ex99-1_012.jpg (GRAPHIC) — 317KB
- ex99-1_013.jpg (GRAPHIC) — 242KB
- ex99-1_014.jpg (GRAPHIC) — 153KB
- ex99-1_015.jpg (GRAPHIC) — 453KB
- ex99-1_016.jpg (GRAPHIC) — 408KB
- ex99-1_017.jpg (GRAPHIC) — 302KB
- ex99-1_018.jpg (GRAPHIC) — 316KB
- ex99-1_019.jpg (GRAPHIC) — 287KB
- ex99-1_020.jpg (GRAPHIC) — 183KB
- ex99-1_021.jpg (GRAPHIC) — 363KB
- ex99-1_022.jpg (GRAPHIC) — 208KB
- ex99-1_023.jpg (GRAPHIC) — 135KB
- ex99-1_024.jpg (GRAPHIC) — 353KB
- ex99-1_025.jpg (GRAPHIC) — 282KB
- ex99-1_026.jpg (GRAPHIC) — 203KB
- ex99-1_027.jpg (GRAPHIC) — 279KB
- ex99-1_028.jpg (GRAPHIC) — 202KB
- ex99-1_029.jpg (GRAPHIC) — 374KB
- ex99-1_030.jpg (GRAPHIC) — 279KB
- ex99-1_031.jpg (GRAPHIC) — 285KB
- ex99-1_032.jpg (GRAPHIC) — 262KB
- ex99-1_033.jpg (GRAPHIC) — 506KB
- ex99-1_034.jpg (GRAPHIC) — 246KB
- ex99-1_035.jpg (GRAPHIC) — 205KB
- ex99-1_036.jpg (GRAPHIC) — 256KB
- ex99-1_037.jpg (GRAPHIC) — 198KB
- ex99-1_038.jpg (GRAPHIC) — 270KB
- ex99-1_039.jpg (GRAPHIC) — 241KB
- ex99-1_040.jpg (GRAPHIC) — 269KB
- ex99-1_041.jpg (GRAPHIC) — 210KB
- ex99-1_042.jpg (GRAPHIC) — 257KB
- 0001213900-24-033533.txt ( ) — 16370KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: April 16, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 3